US 12263225
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
granted A61KA61K2039/505A61K31/713
Quick answer
US patent 12263225 (Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy) held by Dyne Therapeutics, Inc. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K31/713, A61K47/10, A61K47/549